<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cell Therapy on FinanClub</title>
    <link>https://finan.club/tags/cell-therapy/</link>
    <description>Recent content in Cell Therapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 12 Feb 2024 09:13:07 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cell-therapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Mon, 12 Feb 2024 09:13:07 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:16
Chances: Iovance&amp;rsquo;s surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma. These biotech innovators have what it takes to soar. Risks: Iovance shares have dropped by double digits over the past three years.</description>
    </item>
    
  </channel>
</rss>
